{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:33:54Z","timestamp":1790253234679,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":154,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Pharmacology and Drug Discovery"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.crphar.2021.100041","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T21:33:04Z","timestamp":1623187984000},"page":"100041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Repurposing approved therapeutics for new indication: Addressing unmet needs in psoriasis treatment"],"prefix":"10.1016","volume":"2","author":[{"given":"Harsha","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi Rajan","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshita","family":"Dalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandraiah","family":"Godugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi Bala","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-4363","authenticated-orcid":false,"given":"Saurabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jdermsci.2012.02.015","article-title":"Simvastatin ointment, a new treatment for skin inflammatory conditions","volume":"66","author":"Adami","year":"2012","journal-title":"J.\u00a0Dermatol. Sci."},{"key":"10.1016\/j.crphar.2021.100041_bib2","doi-asserted-by":"crossref","first-page":"173088","DOI":"10.1016\/j.ejphar.2020.173088","article-title":"Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells","volume":"877","author":"Al-Harbi","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.crphar.2021.100041_bib3","series-title":"Clinical Immunology","first-page":"871","article-title":"Immunology of psoriasis","author":"Albanesi","year":"2019"},{"issue":"10","key":"10.1016\/j.crphar.2021.100041_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1346-8138.2009.00777.x","article-title":"Comorbidities associated with psoriasis: an experience from the Middle East","volume":"37","author":"AL-Mutairi","year":"2010","journal-title":"J.\u00a0Dermatol."},{"key":"10.1016\/j.crphar.2021.100041_bib6","first-page":"867","article-title":"Innate and adaptive immunity and the pathophysiology of psoriasis","volume":"54","author":"Anthony","year":"2006","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.crphar.2021.100041_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04519.x","article-title":"Efficacy of Psoralen UV-A therapy vs. Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J.\u00a0Eur. Acad. Dermatol. Venereol."},{"issue":"5","key":"10.1016\/j.crphar.2021.100041_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-\u03b1, IFN-\u03b3, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"Arican","year":"2005","journal-title":"Mediat. Inflamm."},{"issue":"8","key":"10.1016\/j.crphar.2021.100041_bib9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","article-title":"A\u00a0bibliometric review of drug repurposing","volume":"23","author":"Baker","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.crphar.2021.100041_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.crphar.2021.100041_bib12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/rccm.201302-0388PP","volume":"188","author":"Barnes","year":"2013","journal-title":"Theophylline. American journal of respiratory and critical care medicine"},{"issue":"12","key":"10.1016\/j.crphar.2021.100041_bib13","first-page":"557","article-title":"Antiinflammatory properties of ambroxol","volume":"13","author":"Beeh","year":"2008","journal-title":"Eur. J. Med. Res."},{"issue":"9","key":"10.1016\/j.crphar.2021.100041_bib14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12016-017-8634-3","article-title":"Unmet needs in the field of psoriasis: pathogenesis and treatment","volume":"55","author":"Boehncke","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2133.2005.06645.x","article-title":"Psoriasis: dysregulation of innate immunity","volume":"152","author":"Bos","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.crphar.2021.100041_bib17","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/jid.2009.25","article-title":"Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis","volume":"129","author":"Boy","year":"2009","journal-title":"J.\u00a0Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2018.92","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","volume":"18","author":"Breckenridge","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.crphar.2021.100041_bib19","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib20","first-page":"295","volume":"146","author":"Calzavara-Pinton","year":"2011","journal-title":"Societa italiana di dermatologia e sifilografia"},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib21","first-page":"859","article-title":"A\u00a050% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis","volume":"50","author":"Carlin","year":"2004","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"11\u201312","key":"10.1016\/j.crphar.2021.100041_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.drudis.2012.12.009","article-title":"Predictive methods in drug repurposing: gold mine or just a bigger haystack?","volume":"18","author":"Cavalla","year":"2013","journal-title":"Drug Discov. Today"},{"issue":"23","key":"10.1016\/j.crphar.2021.100041_bib23","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.3390\/ijms21238960","article-title":"A\u00a0molecular perspective on the potential benefits of metformin for the treatment of inflammatory skin disorders","volume":"21","author":"Chang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.crphar.2021.100041_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell. Signal."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1586\/1744666X.2015.1013534","article-title":"Tofacitinib for the treatment of moderate-to-severe psoriasis","volume":"11","author":"Chiricozzi","year":"2015","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0190-9622(03)01136-8","article-title":"Quality of life issues in psoriasis","volume":"49","author":"Choi","year":"2003","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1021\/np5000796","article-title":"New horizons for old drugs and drug leads","volume":"77","author":"Cragg","year":"2014","journal-title":"J.\u00a0Nat. Prod."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1468-3083.2008.03039.x","article-title":"Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort","volume":"23","author":"Dalaker","year":"2009","journal-title":"J.\u00a0Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0923-1811(94)00376-P","article-title":"Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis","volume":"9","author":"De Jong","year":"1995","journal-title":"J.\u00a0Dermatol. Sci."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12016-016-8535-x","article-title":"The inflammatory response in psoriasis: a comprehensive review","volume":"50","author":"Deng","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"5","key":"10.1016\/j.crphar.2021.100041_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1067\/mcp.2001.115446","article-title":"Risks in new drug development: approval success rates for investigational drugs","volume":"69","author":"DiMasi","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J.\u00a0Health Econ."},{"key":"10.1016\/j.crphar.2021.100041_bib33","doi-asserted-by":"crossref","first-page":"118726","DOI":"10.1016\/j.ijpharm.2019.118726","article-title":"Fenoldopam mesylate for treating psoriasis: a new indication for an old drug","volume":"573","author":"Doppalapudi","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib35","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jaad.2003.09.018","article-title":"Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study","volume":"50","author":"Ehrlich","year":"2004","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1586\/14737140.4.2.180","article-title":"Bexarotene: a clinical review","volume":"4","author":"Farol","year":"2004","journal-title":"Expet Rev. Anticancer Ther."},{"issue":"9","key":"10.1016\/j.crphar.2021.100041_bib37","first-page":"504","article-title":"The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives","volume":"9","author":"Feldman","year":"2016","journal-title":"American health & drug benefits"},{"key":"10.1016\/j.crphar.2021.100041_bib38","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0617-1","article-title":"Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen","volume":"12","author":"Giannuzzi","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.crphar.2021.100041_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1996.tb15661.x","article-title":"Oral retinoids\u2014efficacy and toxicity in psoriasis","volume":"135","author":"Gollnick","year":"1996","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.crphar.2021.100041_bib41","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.4049\/jimmunol.0803721","article-title":"IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells","volume":"183","author":"Goodman","year":"2009","journal-title":"J.\u00a0Immunol."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib42","first-page":"260","article-title":"The national psoriasis foundation psoriasis score (NPF-PS) system versus the psoriasis area severity index (PASI) and physician's global assessment (PGA): a comparison","volume":"2","author":"Gottlieb","year":"2003","journal-title":"J.\u00a0Drugs Dermatol. JDD: J. Drugs Dermatol. JDD"},{"issue":"9","key":"10.1016\/j.crphar.2021.100041_bib43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199503023320907","article-title":"Treatment of psoriasis","volume":"332","author":"Greaves","year":"1995","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/0019-5154.160480","article-title":"Prolonged remission of psoriasis with azathioprine pulse therapy","volume":"60","author":"Gupta","year":"2015","journal-title":"Indian J. Dermatol."},{"issue":"8","key":"10.1016\/j.crphar.2021.100041_bib45","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/all.13763","article-title":"A\u00a0biodiversity hypothesis","volume":"74","author":"Haahtela","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.crphar.2021.100041_bib46","first-page":"1","article-title":"The drug repurposing ecosystem: intellectual property incentives, market exclusivity, and the future of new medicines","volume":"20","author":"Halabi","year":"2018","journal-title":"Yale JL & Tech."},{"key":"10.1016\/j.crphar.2021.100041_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of psoriasis: a comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J.\u00a0Autoimmun."},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib48","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.crphar.2021.100041_bib49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Frontiers in oncology"},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib50","first-page":"186","article-title":"In silico methods for drug repurposing and pharmacology","volume":"8","author":"Hodos","year":"2016","journal-title":"Wiley Interdisciplinary Reviews: Systems Biology and Medicine"},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2003.05433.x","article-title":"Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis","volume":"149","author":"Hoefnagel","year":"2003","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib52","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jaad.2018.04.018","article-title":"Topical Janus kinase inhibitors: a review of applications in dermatology","volume":"79","author":"Hosking","year":"2018","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.crphar.2021.100041_bib53","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3389\/fphar.2019.00921","article-title":"Regulatory framework for advanced therapy medicinal products in Europe and United States","volume":"10","author":"Iglesias-Lopez","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib54","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/0008-5472.CAN-09-3950","article-title":"Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-\u03baB pathway and generation of reactive oxygen species","volume":"70","author":"Jin","year":"2010","journal-title":"Canc. Res."},{"issue":"28","key":"10.1016\/j.crphar.2021.100041_bib55","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.2174\/0929867325666180530100332","article-title":"Computational drug repurposing: current trends","volume":"26","author":"Karaman","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2012.06.021","article-title":"Development of paclitaxel-TyroSpheres for topical skin treatment","volume":"163","author":"Kilfoyle","year":"2012","journal-title":"J.\u00a0Contr. Release"},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib57","doi-asserted-by":"crossref","first-page":"268","DOI":"10.5958\/2231-5691.2019.00044.3","article-title":"Repositioning drugs","volume":"9","author":"Kiran","year":"2019","journal-title":"Asian J. Pharmaceut. Res."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib58","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1067\/mjd.2001.114592","article-title":"Physical and psychologic measures are necessary to assess overall psoriasis severity","volume":"45","author":"Kirby","year":"2001","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib59","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0190-9622(99)70363-4","article-title":"Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results","volume":"41","author":"Koo","year":"1999","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.crphar.2021.100041_bib60","first-page":"390","article-title":"Systemic therapy of psoriasis: methotrexate","volume":"112","author":"Kozub","year":"2011","journal-title":"Bratisl. Lek. Listy"},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib61","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/14712598.2.4.431","article-title":"Selective targeting of T cell subsets: focus on alefacept\u2013a remittive therapy for psoriasis","volume":"2","author":"Krueger","year":"2002","journal-title":"Expet Opin. Biol. Ther."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib62","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib63","article-title":"Psoriasis: a comprehensive review","volume":"2","author":"Kuchekar","year":"2011","journal-title":"International Journal of pharmacy & life sciences"},{"key":"10.1016\/j.crphar.2021.100041_bib64","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3908061","article-title":"The role of IL-17 and related cytokines in inflammatory autoimmune diseases","volume":"2017","author":"Kuwabara","year":"2017","journal-title":"Mediat. Inflamm."},{"issue":"7","key":"10.1016\/j.crphar.2021.100041_bib65","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1517\/14728222.2015.1025051","article-title":"Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease","volume":"19","author":"Ladeiras-Lopes","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"21","key":"10.1016\/j.crphar.2021.100041_bib66","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","article-title":"A\u00a0novel targeted T-cell modulator, efalizumab, for plaque psoriasis","volume":"349","author":"Lebwohl","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib67","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jaad.2002.12.002","article-title":"Combination therapy to treat moderate to severe psoriasis","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib68","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/apha.12476","article-title":"Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases","volume":"216","author":"Levite","year":"2016","journal-title":"Acta Physiol."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib69","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2014.04.003","article-title":"Multi-targeted therapy of cancer by niclosamide: a new application for an old drug","volume":"349","author":"Li","year":"2014","journal-title":"Canc. Lett."},{"key":"10.1016\/j.crphar.2021.100041_bib70","series-title":"Mayo Clinic Proceedings","article-title":"Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug","author":"Long","year":"1994"},{"key":"10.1016\/j.crphar.2021.100041_bib71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00680-8","article-title":"A\u00a0network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information","volume":"8","author":"Luo","year":"2017","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.crphar.2021.100041_bib73","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1172\/JCI200318384","article-title":"Azathioprine: old drug, new actions","volume":"111","author":"Maltzman","year":"2003","journal-title":"The Journal of clinical investigation"},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib74","article-title":"Topical treatments for chronic plaque psoriasis","author":"Mason","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"S11","key":"10.1016\/j.crphar.2021.100041_bib75","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.crphar.2021.100041_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000232301","article-title":"Clinical spectrum and severity of psoriasis","volume":"38","author":"Meier","year":"2009","journal-title":"Management of psoriasis"},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib77","first-page":"394","article-title":"Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis","volume":"13","author":"Mesa","year":"2010","journal-title":"Idrugs: the investigational drugs journal"},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib78","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/039463200902200301","article-title":"Anti-TNF-\u03b1 inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events","volume":"22","author":"Murdaca","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib79","doi-asserted-by":"crossref","first-page":"22813","DOI":"10.3402\/jmahp.v2.22813","article-title":"Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications","volume":"2","author":"Murteira","year":"2014","journal-title":"Journal of market access & health policy"},{"key":"10.1016\/j.crphar.2021.100041_bib80","doi-asserted-by":"crossref","first-page":"106215","DOI":"10.1016\/j.intimp.2020.106215","article-title":"Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23\/IL-17A in innate immune cells","volume":"80","author":"Nadeem","year":"2020","journal-title":"Int. Immunopharm."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib81","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2133.2005.06563.x","article-title":"Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks","volume":"152","author":"Naldi","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib82","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4314\/njm.v19i1.54216","article-title":"The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study","volume":"19","author":"Naseri","year":"2010","journal-title":"Niger. J. Med.: journal of the National Association of Resident Doctors of Nigeria"},{"key":"10.1016\/j.crphar.2021.100041_bib83","series-title":"Therapeutic Drug Repurposing, Repositioning and Rescue","volume":"vol. 57","author":"Naylor","year":"2015"},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/17469872.1.1.63","article-title":"The epidemiology of psoriasis","volume":"1","author":"Neimann","year":"2006","journal-title":"Expet Rev. Dermatol."},{"issue":"5","key":"10.1016\/j.crphar.2021.100041_bib85","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","article-title":"Challenges and opportunities of drug repositioning","volume":"34","author":"Novac","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.crphar.2021.100041_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdermsci.2020.05.008","article-title":"The current landscape of psoriasis genetics in 2020","author":"Ogawa","year":"2020","journal-title":"J.\u00a0Dermatol. Sci."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib87","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","article-title":"Drug repurposing: far beyond new targets for old drugs","volume":"14","author":"Oprea","year":"2012","journal-title":"AAPS J."},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib88","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/adt.2015.29011.tiodrrr","article-title":"Computational and practical aspects of drug repositioning","volume":"13","author":"Oprea","year":"2015","journal-title":"Assay Drug Dev. Technol."},{"issue":"3\u20134","key":"10.1016\/j.crphar.2021.100041_bib89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","article-title":"Drug repurposing from an academic perspective","volume":"8","author":"Oprea","year":"2011","journal-title":"Drug Discov. Today Ther. Strat."},{"issue":"2-3","key":"10.1016\/j.crphar.2021.100041_bib90","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/minf.201100023","article-title":"Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing","volume":"30","author":"Oprea","year":"2011","journal-title":"Molecular informatics"},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib91","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09546630510043202","article-title":"Efficacy of 2 weeks' application of theophylline ointment in psoriasis vulgaris","volume":"16","author":"Papakostantinou","year":"2005","journal-title":"J.\u00a0Dermatol. Treat."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib92","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral J anus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib93","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A\u00a0randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib94","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J.\u00a0Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study","volume":"120","author":"Paul","year":"2003","journal-title":"J.\u00a0Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib96","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A\u00a0randomized phase 2a efficacy and safety trial of the topical J anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib97","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib98","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib99","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/17425247.2015.982088","article-title":"Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy","volume":"12","author":"Rahman","year":"2015","journal-title":"Expet Opin. Drug Deliv."},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib101","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1365-2230.2009.03410.x","article-title":"A\u00a0comprehensive review of biomarkers in psoriasis","volume":"34","author":"Rashmi","year":"2009","journal-title":"Clin. Exp. Dermatol.: Clin. Dermatol."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol. Metab. Syndrome"},{"key":"10.1016\/j.crphar.2021.100041_bib103","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.crphar.2021.100041_bib104","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.crphar.2021.100041_bib105","doi-asserted-by":"crossref","first-page":"101691","DOI":"10.1016\/j.jddst.2020.101691","article-title":"Enhanced penetration and improved therapeutic efficacy of bexarotene via topical liposomal gel in imiquimod induced psoriatic plaque model in BALB\/c mice","volume":"58","author":"Saka","year":"2020","journal-title":"J.\u00a0Drug Deliv. Sci. Technol."},{"issue":"5","key":"10.1016\/j.crphar.2021.100041_bib106","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.12276","article-title":"Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses","volume":"168","author":"Samarasekera","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib107","first-page":"36","article-title":"Prospective role of simvastatin on wound healing: review of the literature","volume":"10","author":"Sameh","year":"2018","journal-title":"J.\u00a0Bioequivalence Bioavailab."},{"issue":"4","key":"10.1016\/j.crphar.2021.100041_bib108","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/bib\/bbr021","article-title":"Drug repositioning for orphan diseases","volume":"12","author":"Sardana","year":"2011","journal-title":"Briefings Bioinf."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib109","article-title":"Repositioning drugs and biologics: retargeting old\/existing drugs for potential new therapeutic applications","volume":"4","author":"Sekhon","year":"2013","journal-title":"Journal of Pharmaceutical Education & Research"},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jaad.2002.08.001","article-title":"A\u00a0phase II multicenter clinical trial of systemic bexarotene in psoriasis","volume":"51","author":"Smit","year":"2004","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"3\u20134","key":"10.1016\/j.crphar.2021.100041_bib111","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ddstr.2011.06.008","article-title":"Repositioned drugs: integrating intellectual property and regulatory strategies","volume":"8","author":"Smith","year":"2011","journal-title":"Drug Discov. Today Ther. Strat."},{"issue":"7","key":"10.1016\/j.crphar.2021.100041_bib112","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJMct072317","article-title":"Psoralen and ultraviolet a light therapy for psoriasis","volume":"357","author":"Stern","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib113","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.3595","article-title":"Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks","volume":"20","author":"Strittmatter","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.crphar.2021.100041_bib114","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.intimp.2019.03.035","article-title":"Protective effects of ambroxol in psoriasis like skin inflammation: exploration of possible mechanisms","volume":"71","author":"Sunkari","year":"2019","journal-title":"Int. Immunopharm."},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib115","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/jcp.29413","article-title":"Repurposing an old drug for new use: niclosamide in psoriasis-like skin inflammation","volume":"235","author":"Thatikonda","year":"2020","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"3","key":"10.1016\/j.crphar.2021.100041_bib116","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bjd.15086","article-title":"Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis","volume":"176","author":"Thorneloe","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.crphar.2021.100041_bib117","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1343228","article-title":"The value of drug repositioning in the current pharmaceutical market","volume":"22","author":"Tobinick","year":"2009","journal-title":"Drug News Perspect."},{"issue":"1\u20132","key":"10.1016\/j.crphar.2021.100041_bib118","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0378-5173(91)90176-O","article-title":"Enhanced permeation of theophylline through the skin and its effect on fibroblast proliferation","volume":"70","author":"Touitou","year":"1991","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-020-0245-8","article-title":"Metformin inhibits IL-1\u03b2 secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis","volume":"6","author":"Tsuji","year":"2020","journal-title":"Cell death discovery"},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib120","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1553-2712.2000.tb02039.x","article-title":"Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial","volume":"7","author":"Tumlin","year":"2000","journal-title":"Acad. Emerg. Med."},{"issue":"5","key":"10.1016\/j.crphar.2021.100041_bib121","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.clindermatol.2007.11.006","article-title":"Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine","volume":"26","author":"Warren","year":"2008","journal-title":"Clin. Dermatol."},{"issue":"10","key":"10.1016\/j.crphar.2021.100041_bib122","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1164\/rccm.2009111-699OC","article-title":"Simvastatin as a treatment for pulmonary hypertension trial","volume":"181","author":"Wilkins","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3\u20134","key":"10.1016\/j.crphar.2021.100041_bib123","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ddstr.2011.06.007","article-title":"Intellectual property and other legal aspects of drug repurposing","volume":"8","author":"Witkowski","year":"2011","journal-title":"Drug Discov. Today Ther. Strat."},{"issue":"12","key":"10.1016\/j.crphar.2021.100041_bib124","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.3390\/ijms18122650","article-title":"The immunogenetics of psoriasis and implications for drug repositioning","volume":"18","author":"Xu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.crphar.2021.100041_bib125","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.crphar.2021.100041_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1413-0","article-title":"A\u00a0novel surfactant-free O\/O paclitaxel ointment for the topical treatment of psoriasis","volume":"20","author":"Yin","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"10.1016\/j.crphar.2021.100041_bib127","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0190-9622(84)80314-X","article-title":"The prevalence of psoriasis in the Mongoloid race","volume":"10","author":"Yip","year":"1984","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.crphar.2021.100041_bib128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/imm.12902","article-title":"Immune modulatory effects of statins","volume":"154","author":"Zeiser","year":"2018","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.crphar.2021.100041_bib129","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/1346-8138.13806","article-title":"Critical role of environmental factors in the pathogenesis of psoriasis","volume":"44","author":"Zeng","year":"2017","journal-title":"J.\u00a0Dermatol."}],"container-title":["Current Research in Pharmacology and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257121000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257121000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:49:15Z","timestamp":1762922955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590257121000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":129,"alternative-id":["S2590257121000286"],"URL":"https:\/\/doi.org\/10.1016\/j.crphar.2021.100041","relation":{},"ISSN":["2590-2571"],"issn-type":[{"value":"2590-2571","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing approved therapeutics for new indication: Addressing unmet needs in psoriasis treatment","name":"articletitle","label":"Article Title"},{"value":"Current Research in Pharmacology and Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crphar.2021.100041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100041"}}